Hbm Holdings Ltd. · HKEX:2142
Hbm — H1 2023 Earnings Presentation
45 slides from Hbm's earnings presentation, Aug 28, 2023
Slide 1: Interim Results 2023
INTERIM RESULTS 2023 28 August 2023 HBM HOLDINGS-B, 02142.HK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into in
Slide 3: Agenda
01 1H 2023: Strategic Growth AGENDA 02 Harbour Therapeutics: Strong Execution on Pipeline 03 Nona Biosciences: Technology Drives Therapeutic Innovation 04 Business & Financial Review 05 Outlook 3
Slide 4: 1H 2023: Strategic Growth
1H 2023: Strategic Growth Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 5: Strong Growth Through Innovation & Strategic Focus
Strong Growth Through Innovation & Strategic Focus Portfolio Advancement Platform Upgrade Business Enhancement ➢ Focus on driving key ➢ Harbour Mice®: ➢ Global partnership with clinical programs to major Innovation for MNCs value inflection points upgraded efficiency ➢ Co-development with ➢ Differen
Slide 6: Business Highlights on Harbour Therapeutics
Business Highlights on Harbour Therapeutics Batoclimab (HBM9161) BLA submission Progress in clinical stage assets ➢ 2 new clinical data readouts from Porustobart (HBM4003) Multiple Major Milestone ➢ 2 clinical program advancement milestones - HBM9378 completed subjects dosing of Phase I trial Achiev
Slide 7: Transformational Engine for New Growth Via Nona
Transformational Engine for New Growth Via Nona Business development • ＞30 on going collaboration projects + protein • Global key accounts + cell + payload + nanoparticle Technology services • 20+ projects kick-off • ADC discovery service officially launched • Well-established discovery management s
Slide 8: Sustainable Business Models to Drive Sustainable Value Creation
Sustainable Business Models to Drive Sustainable Value Creation Business Highlights Financial Highlights ✓ Projects advance to late-stage ✓ Revenue growth >40% in 1H of 2022&2023 ✓ Multiple positive readouts ✓ Sustained BD with MNCs and Biotechs ✓ Comprehensive I/O pipeline ✓ Effective control on op
Slide 9: Harbour Therapeutics: Strong Execution on Pipeline
Harbour Therapeutics: Strong Execution on Pipeline Dr. Xiaolu Tao Chief Development Officer
Slide 10: Highly Innovative and Differentiated Global Pipeline
Highly Innovative and Differentiated Global Pipeline Commercial Status Project Target Indication Rights Discovery Pre-Clinical IND Phase I Phase II Phase III BLA Batoclimab Greater China Rights FcRn Myasthenia Gravis BLA submission HBM9161 Out-licensed1 Solid Tumors a Monotherapy Ph 1b/2 Porustobart
Slide 11: Batoclimab (HBM9161) Breakthrough Therapeutics for IgG Mediated Autoimmune Diseases
Batoclimab (HBM9161) Breakthrough Therapeutics for IgG Mediated Autoimmune Diseases Significant Marketing Opportunity in Autoimmune Disease Batoclimab (HBM9161) 60~70 First positive efficacy of FcRn inhibitors in Asian population in patients with Generalized Myasthenia Gravis pathogenic IgG mediated
Slide 12: Batoclimab Provides Promising Value to Myasthenia Gravis Patients
Batoclimab (HBM9161) Provide Promising Value to Myasthenia Gravis Patients 132 adult gMG patients Patients randomized 1:1 to receive 680mg All patients receive initial treatment cycle batoclimab or placebo (Subcutaneous Injection once weekly for 6 weeks) AChR/MuSK antibody positive and negative ………
Slide 13: Porustobart (HBM4003) Next-Gen Anti-CTLA-4 Antibody
Porustobart (HBM4003) Next-Gen Anti-CTLA-4 Antibody with Potential to be the Mainstream of IO Therapeutics MOA1 MOA2 Competitive Advantages Checkpoint Inhibit Treg Depletion 1 Deplete intra-tumoral Treg cells via enhanced ADCC strategy 2 Great safety profile resulted from the reduced systemic drug e
Slide 14: Porustobart Robust Clinical Benefit in Melanoma Patients
Porustobart (HBM4003) Robust Clinical Benefit in Melanoma Patients Robust efficacy observed for HBM4003 + Toripalimab in PD-1 Robust efficacy observed for HBM4003 + Toripalimab in PD-1 naïve melanoma cohort naïve mucosal melanoma subgroup Best Overall Response by RECIST 1.1, n (%) Best Overall Respo
Slide 15: Porustobart Great Opportunities in High-grade NEN/NEC
Porustobart (HBM4003) Great Opportunities in High-grade Neuroendocrine Neoplasm (NEN)/NEC HBM4003 + Toripalimab elicited significant efficacy improvement in HBM4003 + Toripalimab elicited the highest response rate in high- in high-grade NENs patients grade NENs patients Best Overall Response by RECI
Slide 16: Porustobart Clinical Benefit in Advanced HCC Patients
Porustobart (HBM4003) Clinical Benefit in Advanced HCC Patients Robust efficacy observed for HBM4003 + Toripalimab in post-TKIs HCC patients HBM4003 + Toripalimab elicited high response rate in HCC patients Best Overall Response, n(%) RECIST 1.1 mRECIST ORR of various treatments in HCC patients 50 P
Slide 17: Porustobart Pivotal Trial Preparation
Porustobart (HBM4003) Pivotal Trial Preparation Step 1 Step 2 Step 3 Proof of concept in previously Further verification Preparation for Late-stage clinical treated advanced solid tumor in selected solid tumors trial in certain indication Melanoma ▪ Registration studies ▪ Objective responses • High-
Slide 18: HBM1020 (B7H7/HHLA2) An Alternative Immune Escape Mechanism
HBM1020 (B7H7/HHLA2) An Alternative Immune Escape Mechanism Beyond PD-L1 Highlights H2L2 ❑ T cell and NK cell activation activity and excellent in vivo efficacy in humanized tumor models ❑ Widely Expressed in Various Solid Tumors & Reciprocal to the Expression of PD-L1 ❑ Huge potential to treat PD-L
Slide 19: HBM9033 (MSLN) Next-Gen Mesothelin ADC for Solid Tumors
HBM9033 (MSLN) Next-Gen Mesothelin ADC for Solid Tumors Highlights ❑ Unique fully human antibody warhead with improved binding, internalization, blocking activity and less interference by sMSLN ❑ The 4th generation novel payload with tumor-specific cleavable linker and high serum stability ❑ Superio
Slide 20: HBM7022/AZD5863 Novel 2+1 Format from HBICE Platform
HBM7022/AZD5863 Novel 2+1 Format from HBICE® Platform Validated by MNC Highlights ❑ 2+1 format with better activity and potential larger 2022.4 therapeutic window • Out-licensed to 2023.5-7 ❑ Low CD3 and high CLDN18.2 affinity reduce systemic AstraZeneca • US & CN IND exposure and increase distribut
Slide 21: HBM7008 (B7H4x4-1BB) First-in-Class Bispecific Antibody
HBM7008 (B7H4x4-1BB) First-in-Class Bispecific Antibody from HBICE® Platform Highlights ❑ Fully human bispecific antibody from the HBICE® 2022.05 2023.2 platform • First patient • Collaboration ❑ Novel immune escape pathway - First-in-class target dosed in AU with Cullinan (B7H4x4-1BB) ❑ Excellent s
Slide 22: Nona Biosciences: Technology Drives Therapeutic Innovation
Nona Biosciences: Technology Drives Therapeutic Innovation Dr. Yun He Chief Technology Officer
Slide 23: Nona Biosciences Empowers Global Therapeutic Innovation
Nona Biosciences Empowers Global Therapeutic Innovation Mission Leveraging industrial leading technology platforms, Nona Biosciences is committed to provide integrated discovery solution for biotech and Nona: Roman Goddess pharmaceutical companies from Idea to IND (I to I). Who Enables Others to Suc
Slide 24: Three Pillars to Drive Business Achievement in 2023H1
Three Pillars to Drive Business Achievement in 2023H1 >20 new clients Tech Service Tech License Consistently Advances 10 M$ revenue Technology Innovation: Technology ✓ ADC Discovery Platform Innovation ✓ mRNA-encoded HBICE® ✓ Exploration in CAR-T, protein degradation, etc. 24
Slide 25: Expand Harbour Mice Fully Human Antibody Platforms to Emerging Fields
Expand Harbour Mice® Fully Human Antibody Platforms to Emerging Fields HBICE® Cell therapy Multi-specific protein engineering mRNA delivery ADC HCAb Harbour Plus® Mice® sdAb for Infectious radionuclide diagnostics disease antibody ADC AI+ Ab discovery conjugates Novel sdAb-based modalities mRNA HCAb
Slide 26: Nona Biosciences Consistently Advances Technology Innovation
Nona Biosciences Consistently Advances Technology Innovation Conjugation Protein Engineering Delivery Technology Artificial Intelligence Technology Combine human antibody Novel conjugation technology mRNA technology to bring Artificial Intelligence for platforms and protein for bringing new modaliti
Slide 27: Extend Antibody Discovery Platform to Integrated ADC Discovery Platform
Extend Antibody Discovery Platform to Integrated ADC Discovery Platform H2L2 HCAb HBICE Antibody-lead finding and optimization Deep understanding PK studies, in vivo based on Nona’s Ab discovery platform of ADC molecules stability assessment In vitro In vivo Target Antibody ADC pharmacological Bioco
Slide 28: Explore Frontiers in ADC Field
Explore Frontiers in ADC Field Collaborate with global ADC experts to Unveil the advantages of Application of HCAb in XDC for build ADC ecosystem bispecific / biparatopic ADC Diagnosis & Therapy Radiolabeled anti-MSLN HCAb can quickly penetrate into tumors bsAb showed stronger internalization ✓ full
Slide 29: Comprehensive Bispecific Antibody Discovery Workflow
Comprehensive Bispecific Antibody Discovery Workflow to Reinforce Industry-leading HBICE® Platform (HCAb Based Immune Cell Engagers) bsAb Engineering & Antibody Discovery bsAb Format Screening Candidate Selection characterization Functional activity 3000 Tumor inhibition 100 2500 Cytotoxicity % 80 T
Slide 30: Upgrade Next-Gen HBICE to Strengthen Leading Position
Upgrade Next-Gen HBICE® to Strengthen Our Leading Position in Bispecific Antibody Discovery αTAA T Cells CD3 Tumor αAlb Cells 4-1BB αCD3 TAA ✓ mRNA-encoded HCAb-based bi-/tri-specific engagers for in vivo delivery. ✓ Leverage CD3 HCAb to build ✓ Bring more efficient and cost- tri-specific engagers,
Slide 31: Combine mRNA & HBICE Technologies to Create Next-Gen Therapeutics
Combine mRNA & HBICE® Technologies to Create Next-Gen Therapeutics mRNA-encoded TAAxCD3 engager can elicit excellent therapeutic potential with higher response rate, anti-tumor activity and longer treatment duration. ✓ Combination of mRNA technology and Cytotoxicity on Tumor Cells PBMC Humanized Tum
Slide 32: Nona Leverages Industry-leading Technology Platforms
Nona Biosciences Leverages Industry-leading Technology Platforms to Empower Global Therapeutic Innovation Continuous Experienced Rapid Business Clinically Validated Technology Platforms Scientific Team Growth Innovation • 50+ industry and • HCAb PLUS • 3 innovation centers • 20+ new partners academi
Slide 33: Business & Financial Review
Business & Financial Review Mr. Weihao Xu Chief Financial Officer and Chief Business Officer
Slide 34: Significant Global Collaborations Unleashed Powerful Technology
Significant Global Collaborations Unleashed Powerful Technology HBM7022 Continuing Bispecific antibody mRNA collaborations out-license Delivery in ADC COVID-19 Neutralizing Ab COVID-19 Ab out-license co-development HBM7008 Bispecific antibody co-development Multiple ADC Co-development collaborations
Slide 35: Collaboration with Cullinan
Collaboration with Cullinan Co-development on HBM7008 Drives Speed and Delivers both Short/Long Term Values Principal Terms Upfront Payment • $25 million Validation of the assets and company’s Milestone Payment platform • Up to $600 million Integrate the internal and external Royalties resources • U
Slide 36: Nona Biosciences Consistently Builds Innovation Ecosystem
Nona Biosciences Consistently Builds Innovation Ecosystem Technology Innovation 20+ 1H2023 new clients Revenue ~ USD 10 M Licensing 30+ & Service projects ongoing NewCo Incubation HBM × Alpha 36
Slide 37: Value Creation Through Business Development
Value Creation Through Business Development Cash Received Potential Milestones Royalties 2022 - 1H2023 Tiered royalties on > $ 95 M ~$3B potential net sales Potential milestones generated Collaborations achieved from collaborations since 2023 from 2022 to 2023 37
Slide 38: 2023 Interim Results Positive Profit
2023 Interim Results Positive Profit Projected Revenue Profit for the Period Total revenue of the Group increased significantly from Profit for the period was recorded US$2.9 million for the six US$27.6 million for the six months ended 30 June 2022 to months ended 30 June 2023, compared to a loss fo
Slide 39: Collaborations Improve the Efficiency of R&D
Collaborations Improve the Efficiency of R&D USD Mil Research and development costs 83.6 Clinical/Pre-clinical trial Employee costs Research and development costs decreased significantly Others from US$83.6 million for the six months ended 30 June 2022 to US$28.4 million for the six months ended 30
Slide 40: Effective Control on Operation
Effective Control on Operation USD Mil Administrative expenses Employee costs Administrative expenses decreased by US$6.8 million to 15.3 Professional expenses US$8.6 million for the six months ended 30 June 2023 Others This decrease was primarily attributable to : ❑ Decrease in employee cost from U
Slide 41: Healthy Cash Position to Drive Value Creation
Healthy Cash Position to Drive Value Creation Summary of Consolidated Statements of Financial Position USD Mil 30 June 31 December Cash and bank balances 2023 2022 Cash and bank balances increased from US$171.7 million to US179.3$ million. Non-current assets 20.5 23.1 USD Mil Current assets 203.0 20
Slide 42: Outlook
Outlook Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 43: Harbour BioMed Bridging to New Era
Harbour BioMed Bridging to New Era Develop drugs and drug candidates with unique platform and excellent talent, ultimately bring the idea to fruition - Harbour Therapeutic Multiple catalysts expected in next six months ❑ HBM4003 pivotal trial initiation ❑ HBM1020 preliminary safety and efficacy data
Slide 44: HARBOUR cae .
HARBOUR cae . BIOMED
Slide 45: Thank You
HARBOUR BIOMED